Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

19 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-06-30

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis was to check whether baseline anti-E1E2 antibodies were correlated with the on-treatment viral kinetics and could predict virological outcome in treatment-experienced HCV-infected cirrhotic patients receiving protease inhibitor-based triple therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C

NCT00638144

Hepatitis C

UNKNOWN

Autoantibodies and Direct-acting Antivirals

NCT03566966

Viral Hepatitis C Therapy Adverse Effect

COMPLETED

Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy

NCT02788682

Chronic Hepatitis C

COMPLETED

Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy

NCT03226717

Hepatitis C

UNKNOWN

Data Collection and Identification of Infection-responsible Bacterial Resistances in Cirrhotic Patients

NCT03965260

Cirrhosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HCV triple therapy

Cohort of HCV patients who received first-generation protease inhibitor-based triple therapy

Triple therapy

Intervention Type OTHER

Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triple therapy

Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HCV patients with compensated cirrhosis (Child-Pugh A)
* HCV genotype 1
* non-responders to a previous course of interferon (IFN)/ribavirin
* receiving boceprevir or telaprevir